Sugi Predict

Sugi Predict / Compounds / SCHEMBL1829346

SCHEMBL1829346

SCHEMBL1829346

Cc1cc(CC(=O)O)ccc1[N+](=O)[O-]

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 3/20 0.58
▸ L3MBTL1 Q9Y468 3/20 0.49
▸ RAB9A P51151 2/20 0.49
▸ SMN1; SMN2 Q16637 2/20 0.49
▸ NPC1 O15118 1/20 0.49
▸ CYP1A2 P05177 1/20 0.47
▸ MAPT P10636 3/20 0.47
▸ MEN1 O00255 4/20 0.47
▸ KMT2A Q03164 4/20 0.47
▸ ALDH1A1 P00352 3/20 0.47
▸ LMNA P02545 2/20 0.47
▸ BLM P54132 2/20 0.45
▸ KDM4E B2RXH2 3/20 0.44
▸ GAA P10253 2/20 0.44
▸ HSD17B10 Q99714 2/20 0.44
▸ POLB P06746 2/20 0.44
▸ TDP1 Q9NUW8 2/20 0.44
▸ RGS12 O14924 1/20 0.44
▸ HPGD P15428 1/20 0.44
▸ NFKB1 P19838 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14777639 1.00 TSHR (0.58) TSHRL3MBTL1RAB9ASMN1; SMN2NPC1
SCHEMBL2597801 0.94 TSHR (0.53) TSHRL3MBTL1RAB9ASMN1; SMN2NPC1
SCHEMBL9550639 0.89 TSHR (0.58) TSHRL3MBTL1RAB9ASMN1; SMN2NPC1
SCHEMBL1492458 0.87 TSHR (0.58) TSHRRAB9ASMN1; SMN2NPC1CYP1A2
SCHEMBL30641922 0.87 TSHR (0.58) TSHRRAB9ASMN1; SMN2NPC1CYP1A2
SCHEMBL29100214 0.85 TSHR (0.53) TSHRL3MBTL1RAB9ASMN1; SMN2NPC1
SCHEMBL30764869 0.85 TSHR (0.53) TSHRL3MBTL1RAB9ASMN1; SMN2NPC1
SCHEMBL1865824 0.84 CASP6 (0.55) TSHRCYP1A2MAPTMEN1KMT2A
SCHEMBL8790409 0.84 TSHR (0.55) TSHRL3MBTL1RAB9ASMN1; SMN2NPC1
SCHEMBL5465423 0.83 PDGFRB (0.53) TSHRL3MBTL1RAB9ASMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120136739-A Amitraz hapten, amitraz antigen, amitraz antibody, detection device, preparation and application thereof 广东江门中医药职业学院 2025-06-13 — — CN claimed
EP-3573972-B1 RORGAMMA MODULATORS AND USES THEREOF GENFIT (FR) 2026-01-14 — — EP disclosed
EP-3590516-B1 ANTITUMOR-EFFECT ENHANCER USING PYRAZOLO[3,4-D]PYRIMIDINE COMPOUND TAIHO PHARMACEUTICAL CO LTD (JP) 2025-09-03 — — EP disclosed
CN-120136739-A Amitraz hapten, amitraz antigen, amitraz antibody, detection device, preparation and application thereof 广东江门中医药职业学院 2025-06-13 — — CN disclosed
US-20240424111-A1 Degrader Compounds and Uses Thereof CALICO LIFE SCIENCES LLC (US) 2024-12-26 — — US disclosed
US-20240383886-A1 Protein Tyrosine Phosphatase Degraders and Methods of Use Thereof ABBVIE INC. 2024-11-21 — — US disclosed
EP-4359409-A1 DEGRADER COMPOUNDS AND USES THEREOF Calico Life Sciences LLC (US) 2024-05-01 — — EP disclosed
EP-3426246-B1 THIAZOLIDINONE COMPOUNDS AND USE THEREOF NATIONAL HEALTH RES INST (TW) 2024-05-01 — — EP disclosed
US-11696917-B2 Agent enhancing antitumor effect using pyrazolo[3,4-d]pyrimidine compound TAIHO PHARMACEUTICAL CO., LTD. (JP) 2023-07-11 — — US disclosed
CN-116194453-A Protein tyrosine phosphatase degrading agent and method of use thereof 卡里科生命科学有限责任公司 2023-05-30 — — CN disclosed
US-7625948-B2 Ester compound and medicinal use thereof JAPAN TOBACCO INC. (JP) 2009-12-01 — — US disclosed
US-7625948-B2 Ester compound and medicinal use thereof JAPAN TOBACCO INC. (JP) 2009-12-01 — — US disclosed
US-20060293343-A1 Pyrimidine derivatives ASAHI KASEI PHARMA CORPORATION (JP) 2006-12-28 — — US disclosed
US-20050075367-A1 Ester compound and medicinal use thereof JAPAN TOBACCO INC. (JP) 2005-04-07 — — US disclosed
EP-1479666-A1 ESTER COMPOUND AND MEDICINAL USE THEREOF JAPAN TOBACCO INC. (JP) 2004-11-24 — — EP disclosed
CN-1042421-C Acridine derivatives GLAXO LAB SA (FR) 1999-03-10 — — CN disclosed
EP-0569380-B1 ACRIDINE DERIVATIVES GLAXO LAB SA (FR) 1997-05-28 — — EP disclosed
US-5604237-A IMPROVE OR INCREASE EFFICACY OF ANTITUMOR AGENT, INCREASE OR RESTORE SENSITIVITY OF TUMOR TO ANTITUMOR AGENT, REVERSE OR REDUCE RESISTANCE OF TUMOR TO ANTITUMOR AGENT LABORATOIRES GLAXO SA (FR) 1997-02-18 — — US disclosed
CN-1081181-A Acridine derivatives GLAXO LAB SA (FR) 1994-01-26 — — CN disclosed
EP-0494623-A1 Acridine derivatives LABORATOIRES GLAXO SA (FR) 1992-07-15 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11696917-B2 Agent enhancing antitumor effect using pyrazolo[3,4-d]pyrimidine compound ZYX, DPYD, ZFX TSHR 2852/4885L3MBTL1 3064/4885RAB9A 2320/4885
US-20240383886-A1 Protein Tyrosine Phosphatase Degraders and Methods of Use Thereof PTPN5, PTPN1, PTPN2 TSHR 729/4885L3MBTL1 3666/4885RAB9A 2970/4885
US-20060293343-A1 Pyrimidine derivatives PDE4A, PDE4B, PDE5A TSHR 3798/4885L3MBTL1 4015/4885RAB9A 2501/4885
US-20050075367-A1 Ester compound and medicinal use thereof LIPC, CES1, MTTP TSHR 621/4885L3MBTL1 363/4885RAB9A 1406/4885
US-20240424111-A1 Degrader Compounds and Uses Thereof PTPN1, PTPN2, PTPN5 TSHR 844/4885L3MBTL1 3192/4885RAB9A 2631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.